RIVASTIGMIN Mepha Patch 13.3 mg/24h TTS 30 pce
7680687950046
CH-68795
N06DA03
01.99.0.
Reimbursement limitations:
THERAPIEBEG
En début de thérapie, application par ex. d'un test minimental.
Première évaluation intermédiaire après trois …
1 / 3
google
Details
- Product number
- 6879503
- CPT
- -
- Packaging group
- 30
- Unit
- Pflaster
- Composition
- rivastigminum 19.2 mg, 2-ethylhexylis acrylatis et vinylis acetatis polymerisatum, polyisobutylenum, silica colloidalis anhydrica, paraffinum perliquidum, Trägermaterial: polyethylenum/aluminium polyesterum, polyesterum, ad praeparationem pro 12.8 cm², cum liberatione 13.3 mg/24h.
Articles (1)
Rivastigmin-Mepha Patch 13.3 mg/24 h, Transdermale Pflaster
Pflaster
30
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
19.2 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HPFLA |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 59.40
Specialties list
Yes
Generic
Yes
Reimbursement limitation
SL addition date:
01/03/2023
Authorization holder
Mepha Pharma AG
4051 Basel
Authorization information
- Swissmedic authorization number
- 68795
- Drug name
- Rivastigmin-Mepha Patch, Transdermale Pflaster
- Galenic form
- TRAP
- ATC Code
- N06DA03
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 15/11/2022
- Authorization expiration date
- 14/11/2027
- IT number
- 01.99.0.
- Domain
- Human medicine
Packaging details
- Description (FR)
- RIVASTIGMIN Mepha Patch 13.3 mg/24h TTS 30 pce
- Description (DE)
- RIVASTIGMIN Mepha Patch 13.3 mg/24h TTS 30 Stk
- Market launch
- 15/11/2022
- Narcotic (BTM)
- No